Edition:
United Kingdom

Eagle Pharmaceuticals Announces Positive Results Of Pre-Clinical Study Conducted To Evaluate Effects Of Ryanodex In Acute Radiation Syndrome (ARS)


Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF PRE-CLINICAL STUDY CONDUCTED TO EVALUATE EFFECTS OF RYANODEX IN ACUTE RADIATION SYNDROME (ARS).EAGLE PHARMACEUTICALS INC - TO EXPLORE ARS INDICATION TO TREAT INDIVIDUALS EXPOSED TO HIGH DOSES OF RADIATION.EAGLE PHARMACEUTICALS INC - PLANS TO CONDUCT FURTHER RESEARCH FOR TREATMENT OF POST-IRRADIATION HEMATOPOIETIC SYNDROME.EAGLE PHARMACEUTICALS INC - RYANODEX TREATMENT GROUP HAD OVERALL LESS MORTALITY POST-TREATMENT THAN NON-TREATED ANIMALS WITH ARS.EAGLE PHARMACEUTICALS - ADDITIONAL RESEARCH ONGOING TO EVALUATE HEMATOPOIETIC SYNDROME IN CERTAIN CANCER PATIENTS UNDERGOING RADIATION THERAPY. 

Company Quote

52.89
 --
22 May 2019